Table 2.

Univariate correlation analysis of telomere length with clinical and biochemical characteristics of NFPA patients and controls.

Telomere length	NFPA (N = 114)			Controls (N = 106)
	β	P	N	β	P	N
Age	0.17*	<0.001*	114*	0.08*	0.003*	106*
BMI	0.017	0.167	114	0.012	0.092	106
Gender	0.000	0.896	114	0.005	0.467	106
Current smoking status	0.003	0.556	104	0.001	0.739	100
Diabetes mellitus type 2	0.040*	0.032*	114*	0.015	0.232	104
Fasting glucose	0.020	0.13	99	NA	NA	NA
HbA1c	0.051*	0.04*	83*	NA	NA	NA
Arterial hypertension	0.120*	<0.001*	114*	0.000	0.965	104
Number of antihypertensive drugs	0.130*	<0.001*	114*	NA	NA	NA
Systolic blood pressure	0.060*	0.009*	107*	NA	NA	NA
Diastolic blood pressure	0.006	0.424	107	NA	NA	NA
Waist-to-hip ratio	0.017	0.294	66	NA	NA	NA
Waist circumference	0.030*	0.09*	84*	NA	NA	NA
Total leukocyte count	0.050*	0.03*	107*	NA	NA	NA
Time since diagnosis	0.017	0.255	79	NA	NA	NA
Pituitary insufficiency of any axis	0.014	0.202	114	NA	NA	NA
Overt sex steroid deficiency	0.012*	0.178*	114*	NA	NA	NA
Hypothyroidism	0.005	0.472	114	NA	NA	NA
Overt growth hormone deficiency	0.006	0.412	114	NA	NA	NA
Growth hormone dose	0.020	0.368	36	NA	NA	NA
IGF-1-SDS	0.004	0.526	99	NA	NA	NA
Adrenal insufficiency	0.001	0.731	114	NA	NA	NA
Daily total hydrocortisone dose	0.060*	0.091*	52*	NA	NA	NA
Diabetes insipidus	0.003	0.551	114	NA	NA	NA
Triglycerides	0.008	0.395	97	NA	NA	NA
Current statin use	0.030*	0.079*	114*	NA	NA	NA
Total cholesterol	0.007	0.388	109	NA	NA	NA
HDL cholesterol	0.003	0.580	94	NA	NA	NA
LDL cholesterol	0.002	0.662	93	NA	NA	NA

*Parameters which showed a linear correlation at least on trend level (P < 0.1) with telomere length.